{"id":"NCT01799993","sponsor":"Bayer","briefTitle":"Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia","officialTitle":"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-13","primaryCompletion":"2017-04-07","completion":"2017-04-07","firstPosted":"2013-02-27","resultsPosted":"2018-06-26","lastUpdate":"2018-07-23"},"enrollment":725,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pneumonia, Bacterial"],"interventions":[{"type":"DRUG","name":"Amikacin Inhalation Solution (BAY41-6551)","otherNames":[]},{"type":"DRUG","name":"Aerosolized Placebo","otherNames":[]}],"arms":[{"label":"Amikacin inhale (BAY41-6551)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and more effective than placebo (aerosolized normal saline) administered as an aerosol by the PDDS Clinical every 12 hours, in intubated and mechanically-ventilated patients with Gram-negative Pneumonia. The secondary endpoint objectives are to evaluate the superiority of aerosolized BAY 41-6551 versus aerosolized placebo in pneumonia-related mortality, the Early Clinical Response at Day 10, the days on ventilation, and the days in the intensive care unit (ICU).","primaryOutcome":{"measure":"Number of Participants Surviving Through LFU Visit","timeFrame":"Up to 28-32 days after start of study treatment","effectByArm":[{"arm":"Amikacin Inhale (BAY41-6551)","deltaMin":191,"sd":null},{"arm":"Placebo","deltaMin":196,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4263"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":65,"countries":["United States","Australia","Brazil","Canada","Colombia","Czechia","Mexico","Philippines","South Korea","Taiwan","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["31866328"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":101,"n":353},"commonTop":["Anaemia","Hypokalaemia","Constipation","Diarrhoea","Pyrexia"]}}